18-19 novembre 2022

CONGRESSO ATBV 2022

Filmati dei lavori

 

I giornata

ABOVE AND BEYOND LDL CHOLESTEROL

Gaetano Maria De Ferrari, Maddalena Lettino

 

Optimal Use of Statins, Ezetimibe, and Bempedoic Acid in Clinical Practice – Paolo Calabrò

Evolutions of PCSK9 Inhibition – Giuseppe Musumeci

Icosapent ethyl is different than PolyUnsaturated Fatty Acids: Understanding REDUCE IT – Giuseppe Patti

The future is now: Lipoprotein (a) inhibition and more! – Alberico Catapano

Discussion

 

 

SPOTLIGHT SESSION: UPDATES ON ATHEROSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY FROM ESC AND AHA 2022

Claudio Ceconi, Anna Franzone

 

Late-Breaking Updates from ESC.2022 – Ilaria Cavallari

Late-Breaking Updates from AHA.22 – Felice Gragnano

 

 

JOINT ATBV-ACVC SESSION: MANAGEMENT OF ANTITHROMBOTHIC
THERAPY IN CRITICALLY ILL PATIENTS

Ingo Ahrens, Maddalena Lettino

 

Antithrombothic Strategies in Patients with Mechanical Circulatory Support – Christophe Vendenbriele

Atrial Fibrillation in Critically Ill Patients – Kurt Huber

Discussion

 

 

SPOTLIGHT SESSION: ESTABLISHED AND EMERGING PARENTERAL
ANTIPLATELET AGENTS

Alberto Menozzi, Raffaele Piccolo

 

Cangrelor and Glycoprotein IIb/IIIa Inhibitors: Different Drugs, Different Roles – Leonardo De Luca

Future Pre-Hospital Strategies: Selatogrel and RUC-4 – Felice Gragnano

Discussion

 

 

THE WORST CHALLENGES REVEAL THE BEST CLINICIANS: TRANSLATING EVIDENCE AND EXPERIENCE TO THE INDIVIDUAL PATIENT

Walter Ageno, Gaetano Maria De Ferrari

 

Challenge #1: Intracranial Hemorrage with a Mechanical Mitral Valve – Marco Mennuni; The Expert Responds: Stefano De Servi

Challenge #3: Unplanned Abdominal Surgery After High Risk PCI – Claudio Montalto; The Expert Responds: Stefano Savonitto

SPECIAL SESSION WITH THE PRINCIPAL INVESTIGATORS INSIGHTS FROM THE INSIDE: FROM STUDY DESIGN TO EVIDENCE INTERPRETATION

Sergio Leonardi, Williem J.M. Dewilde

 

RE-DUAL PCI: A Tale of Two Doses and Drugs – Christopher Cannon, interviewed by Andrea Rubboli

AUGUSTUS, finally a factorial design – Renato Lopes, interviewed by Sergio Leonardi

Last but not least: ENTRUST-AF PCI – Pascal Vranckx, interviewed by Marco Valgimigli

 

 

II giornata

 

EVOLVING ANTITHROMBOTIC STRATEGIES IN PATIENTS WITH ACUTE AND CHRONIC CORONARY SYNDROME: TOWARD PERSONALIZED MEDICINE?

Claudio Fresco, Luigi Oltrona Visconti

 

Is Guided Antiplatelet Therapy Ready for Prime Time? – Davide Capodanno

Indication and Timing of P2Y12 Inhibitors Monotherapy After ACS – Leonardo Bolognese

Vascular Dose of Rivaroxaban: From Evidence to Pratcice – Marco Ferlini

Bridgining Antithrombothic Strategies in Patients with Coronary Stent Requiring Surgery – Giuseppe Musumeci

Discussion

 

 

BURNING HEART

Giuseppe Patti, Aldo Pietro Maggioni

 

Repurposing Colchicine: From Inflammation to Acute and Chronic Coronary Syndrome Use – Massimo Imazio

Inflammatory Citokines, Now an Actionable Target – Pasquale Perrone Filardi

State-of-the-Art Lecture: Targeting Inflammation in Cardiovascular Diseases – Raffaele De Caterina

Discussion

 

Joint Session with ESC WG on Thrombosis-LATE-BREAKING INNOVATIONS IN ANTITHROMBOTHIC THERAPY

Andrea Rubboli, Bianca Rocca

 

Novel Targets in the Coagulation Pathway – Diana Gorog

Factor XIa Inhibition: a Novel Bleeding Minimize Strategy – Gianluca Campo

 

 

OPTIMAL ANTITHROMBOTHIC THERAPY IN PATIENTS UNDERGOING STRUCTURAL HEART PROCEDURES

Alaide Chieffo, Ferdinando Varbella

 

Transcathether Aortic Valve Replacement – Anna Franzone

Left Atrial Appendage Occlusion and Exclusion – Francesco Costa

Mitral Valve Procedures – Gabriele Crimi

Special Lecture: The Physician-Patient Alliance – Claudio Cuccia, interviewed by Sergio Leonardi

 

 

 

SPOTLIGHT SESSION: REPURPOSING ANTI-DIABETIC DRUGS: PRESENT AND FUTURE USE OF SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS AND GLP-1 RECEPTOR AGONISTS